Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Jan;45(1):54–60. doi: 10.1038/bjc.1982.7

Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors.

C Burtin, P Scheinmann, J C Salomon, G Lespinats, P Canu
PMCID: PMC2010957  PMID: 7059465

Abstract

C3H and C57 BL/6 mice carrying methylcholanthrene-induced fibrosarcomas were injected i.p. daily with histamine, metiamide (anti-histamine type-2 receptor), histamine + metiamide, mepyramine (anti-histamine type-1 receptor), serotonin and methysergide (anti-serotonin). Inhibition of tumour growth and lengthened survival were observed with histamine and histamine + metiamide. The best results (both on tumour growth and survival) were obtained with serotonin. Survival was increased by metiamide and decreased by mepyramine and methysergide. In histamine-treated and in serotonin-treated mice, histological studies of the tumours showed large and numerous foci of haemorrhagic necrosis. Stimulation of histamine type-1 or serotonin receptors and inhibition of histamine type-2 receptors play a beneficial role in the host's defence against tumours.

Full text

PDF
54

Images in this article

57Fig. 4
on p.57
58Fig. 5
on p.58
58Fig. 6
on p.58

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burtin C., Scheinmann P., Salomon J. C., Lespinats G., Frayssinet C., Lebel B., Canu P. Increased tissue histamine in tumour-bearing mice and rats. Br J Cancer. 1981 May;43(5):684–688. doi: 10.1038/bjc.1981.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Burtin C., Scheinmann P., Salomon J. C., Lespinats G., Loisillier F., Canu P. The influence of intraperitoneal injections of histamine on tumour growth in fibrosarcoma-bearing mice. Cancer Lett. 1981 Apr;12(3):195–201. doi: 10.1016/0304-3835(81)90068-9. [DOI] [PubMed] [Google Scholar]
  3. Cimetidine, the immune system, and cancer. Lancet. 1981 Apr 18;1(8225):900–901. [PubMed] [Google Scholar]
  4. Dvorak A. M., Galli S. J., Galli A. S., Hammond M. E., Churchill W. H., Jr, Dvorak H. F. Tumor-basophil interactions in vitro--a scanning and transmission electron microscopic study. J Immunol. 1979 Jun;122(6):2447–2457. [PubMed] [Google Scholar]
  5. Farram E., Nelson D. S. Mouse mast cells as anti-tumor effector cells. Cell Immunol. 1980 Oct;55(2):294–301. doi: 10.1016/0008-8749(80)90162-8. [DOI] [PubMed] [Google Scholar]
  6. Gifford R. R., Ferguson R. M., Voss B. V. Cimetidine reduction of tumour formation in mice. Lancet. 1981 Mar 21;1(8221):638–640. doi: 10.1016/s0140-6736(81)91555-5. [DOI] [PubMed] [Google Scholar]
  7. Henderson W. R., Chi E. Y., Jong E. C., Klebanoff S. J. Mast cell-mediated tumor-cell cytotoxicity. Role of the peroxidase system. J Exp Med. 1981 Mar 1;153(3):520–533. doi: 10.1084/jem.153.3.520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lynch N. R., Castes M., Astoin M., Salomon J. C. Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br J Cancer. 1978 Oct;38(4):503–512. doi: 10.1038/bjc.1978.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lynch N. R., Salomon J. C. Passive local anaphylaxis: demonstration of antitumor activity and complementation of intratumor BCG. J Natl Cancer Inst. 1977 Apr;58(4):1093–1098. doi: 10.1093/jnci/58.4.1093. [DOI] [PubMed] [Google Scholar]
  10. Lynch N. R., Salomon J. C. Tumour-associated inhibition of immediate hypersensitivity reactions in mice. Immunology. 1977 May;32(5):645–650. [PMC free article] [PubMed] [Google Scholar]
  11. Osband M. E., Hamilton D., Shen Y. J., Cohen E., Shlesinger M., Lavin P., Brown A., McCaffrey R. Successful tumour immunotherapy with cimetidine in mice. Lancet. 1981 Mar 21;1(8221):636–638. doi: 10.1016/s0140-6736(81)91554-3. [DOI] [PubMed] [Google Scholar]
  12. Plaut M., Lichtenstein L. M., Gillespie E., Henney C. S. Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J Immunol. 1973 Aug;111(2):389–394. [PubMed] [Google Scholar]
  13. Poupon M. F., Lespinats G., Kolb J. P., Payelle B. Immunity to a 3-methylcholanthrene-induced fibrosarcoma in the C57BL/6 mouse: in vivo analysis by the adoptive tumor neutralization test. J Natl Cancer Inst. 1979 Apr;62(4):989–994. [PubMed] [Google Scholar]
  14. Rocklin R. E., Breard J., Gupta S., Good R. A., Melmon K. L. Characterization of the human blood lymphocytes that produce a histamine-induced suppressor factor (HSF). Cell Immunol. 1980 May;51(2):226–237. doi: 10.1016/0008-8749(80)90255-5. [DOI] [PubMed] [Google Scholar]
  15. Scheinmann P., Lebel B., Lynch N. R., Salomon J. C., Paupe J. R., Burtin C. Histamine levels in blood and other tissues of male and female C3H mice. II. Mice carrying a 3-methyl-cholanthrene-induced tumor [proceedings]. Agents Actions. 1979 Apr;9(1):95–96. doi: 10.1007/BF02024138. [DOI] [PubMed] [Google Scholar]
  16. Schwartz A., Askenase P. W., Gershon R. K. The effect of locally injected vasoactive amines on the elicitation of delayed-type hypersensitivity. J Immunol. 1977 Jan;118(1):159–165. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES